Skip to content
Catalyst Biosciences
Primary Menu
About
Overview
Management Team
Board of Directors
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Contact
ISTH 2019 – Quality of Life of Hemophilia Patients with Inhibitors – Opportunities for Improvement
Post navigation
Previous:
AAV Based Hemophilia B Gene Therapy in Mice Using FIX-CB2679d-GT
Next:
ISTH 2019 – Phase 2/3 Trial of Subcutaneous Engineered FVIIa Marzeptacog Alfa (Activated) in Hemophilia A or B with Inhibitors: Efficacy, Safety and Pharmacokinetics
X
Previous
Next
